AOH1996 for the Treatment of Refractory Solid Tumors

Official title

First in Human Phase 1 Study of AOH1996 in Patients With Refractory Solid Tumors

Overview

This phase I trial studies the side effects and best dose of AOH1996 in treating patients with solid tumors that do not respond to treatment (refractory). AOH1996 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Detailed description

PRIMARY OBJECTIVES:

I. To determine the maximum tolerated dose (MTD) and the dose limiting toxicities (DLT) of AOH1996.

II. To establish the recommended phase 2 dose of AOH1996.

III. To establish the recommended phase 2 dose of AOH1996 when given in conjunction with a TKI for NSCLC.

SECONDARY OBJECTIVES:

I. To determine the pharmacokinetics of AOH1996. II. To evaluate for preliminary efficacy of AOH1996. III. To evaluate response rate and disease control rate in solid tumors.

EXPLORATORY OBJECTIVE:

I. To determine pharmacodynamics parameters (alteration of gammaH2AX, downregulation of Myc) of AOH1996.

OUTLINE: This is a dose-escalation study.

Patients receive AOH1996 orally (PO) twice daily (BID) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 30 days.

Interventions

• Drug PCNA Inhibitor AOH1996
  Given PO

Primary outcome measures

• Incidence of adverse events (AEs) [Time frame: Up to 30 days after last study drug is given]
• Dose limiting toxicities [Time frame: Up to 28 days (cycle 1)]

Secondary outcome measures (4)

• Response rate [Time frame: Up to 2 years]
• Progression-free survival [Time frame: Assessed up to 2 years]
• Overall survival [Time frame: Assessed up to 2 years]
• Time to treatment failure [Time frame: Assessed up to 2 years]

Eligibility criteria

Inclusion criteria

Informed Consent and Willingness to Participate

• 1\. Documented informed consent by the participant
• 2\. Willingness to permit study team to obtain and use archival tissue, if already existing

Age Criteria, Performance Status and Life Expectancy

• 3\. Age: ≥ 18 years
• 4\. ECOG performance status ≤ 2
• 5\. Life expectancy of > 3 months

Nature of Illness and Treatment History \_\_6. Patients with solid tumors failing standard therapies or patients refusing standard treatments (exception: Part B NSCLC combination (EGFR TKI + AOH1996) cohort: patients with stable disease or better on EGFR TKI for at least 2 months)

Contraception

\_\_7. Agreement by females and males of childbearing potential\* to use an adequate method of birth control (hormonal contraception is inadequate) or abstain from heterosexual activity for the course of the study through 30 days after the last dose of study medication. See Appendix B for guidelines.

\- Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only).

Laboratory Criteria (to be performed within 14 days prior to Day 1)

• 8\. ANC ≥ 1,500/mm3
• 9\. Platelets ≥ 100,000/mm3 :
• 10\. Total serum bilirubin ≤ 1.5 x ULN
• 11\. AST =< 1.5 x ULN or =< 3 x ULN with liver metastases
• 12\. ALT =< 1.5 x ULN or =< 3 x ULN with liver metastases
• 13\. Creatinine clearance of ≥ 60 mL/min per 24 hour urine or the Cockcroft-Gault
• 14\. Women of childbearing potential (WOCBP): negative urine or serum pregnancy test If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required

Exclusion criteria

Concomitant Medications/Therapies \_\_1. Dietary/herbal supplements

• 2\. Other investigational products or chemotherapy. Exception: EGFR TKI in the NSCLC expansion cohort is allowed.
• 3\. Warfarin
• 4\. Current or planned use of agents contraindicated for use with strong CYP3A4 inducers
• 5\. Strong inhibitors or inducers of CYP2C9
• 6\. Strong inhibitors or inducers of CYP3A

Other Illnesses and Conditions

• 7\. Issues with tolerating oral medication (e.g., inability to swallow pills, malabsorption issues, ongoing nausea or vomiting).
• 8\. Women who are or are planning to become pregnant or breastfeed
• 9\. Known allergy to any of the components within the study agents and/or their excipients.
• 10\. No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for three years.
• 11\. Intercurrent or historic medical condition that increases subject risk in the opinion of the Investigator. Eligibility may be revisited for intercurrent medical conditions once resolution/recovery is deemed adequate by the investigator (e.g. recovery from major surgery, completion of treatment for severe infection).

Noncompliance

\_\_12. Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics).

\*\*Eligibility should be confirmed per institutional policies.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Treatment

Study locations

United States · 3 centers

• Honor Health Research and Innovation Institute — Scottsdale
• City of Hope Medical Center — Duarte
• City of Hope at Long Beach Elm — Long Beach

Identifiers

NCT: NCT05227326 · 21310 · NCI-2021-14102 · 21310 · P30CA033572

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗